Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 12, 2022 06:50 ET | Source: Bright Minds Biosciences

Bright Minds Biosciences to Host Key Opinion Leader Symposium on Dravet Syndrome

-- Review of Phase I ready BMB-101 and upcoming milestones -- -- Webcast to be held on May 19, 2022, 4:00pm ET -- VANCOUVER, British Columbia, May 12, 2022 (GLOBE NEWSWIRE) -- Bright Minds...
August 09, 2016 16:01 ET | Source: Zogenix, Inc.

Zogenix Provides Corporate Update and Reports Second Quarter 2016 Financial Results

EMERYVILLE, Calif., Aug. 09, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS)...
June 21, 2016 08:00 ET | Source: Zogenix, Inc.

Zogenix Announces Agreement to Refinance Debt, Further Increasing Company’s Expected 2017 Cash Balance

- Interest-only repayment provision results in $10 million increase to Zogenix’s expected cash balance at the end of 2017 - EMERYVILLE, Calif., June 21, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc....
June 07, 2016 08:00 ET | Source: Zogenix, Inc.

Zogenix Announces Initiation of Multi-National Phase 3 Clinical Trial for ZX008 in Dravet Syndrome

EMERYVILLE, Calif., June 07, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders,...
May 05, 2016 08:00 ET | Source: Zogenix, Inc.

Zogenix Announces New Efficacy and Safety Data on ZX008 for Treatment of Seizures in Dravet Syndrome

Patient and Caregiver Sleep Quality and Quality of Life Data Reported for First Time New Clinical Data Presented at 14th International Child Neurology Congress on the Use of Low-Dose Fenfluramine...
January 19, 2016 08:00 ET | Source: Zogenix, Inc.

Zogenix Receives Fast Track Designation From FDA for Development of ZX008 in Dravet Syndrome

EMERYVILLE, Calif., Jan. 19, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today...
October 03, 2013 10:00 ET | Source: Nuvilex, Inc.

Nuvilex, Inc.'s Marijuana Research Into Cannabidiol Could Lead to Many Successes

NEW YORK, NY--(Marketwired - Oct 3, 2013) - Nuvilex, Inc. (OTCQB: NVLX) formed its subsidiary, Medical Marijuana Sciences, Inc., to study the medical applications of marijuana, and more...
March 09, 2011 09:24 ET | Source: CeCe Cares - Pediatric Epilepsy Foundation

CeCe Cares Pediatric Epilepsy Foundation Honors the 1st Anniversary of CeCe Cunningham's Passing

CHICAGO, March 9, 2011 (GLOBE NEWSWIRE) -- CeCe Cares Pediatric Epilepsy Foundation, a nonprofit organization created to provide comfort to children diagnosed with Pediatric Epilepsy, help families...